logo

For the Inventor, By the Inventor

Windham, NH, United States of America

Jeffrey Scott DePue

This inventor holds 7 USPTO granted patents and 5 published patent applications. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2025-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jeffrey Scott DePue. Retrieved from https://idiyas.com/inventor/jeffrey-scott-depue

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 7 

% Patents Active = 71.4

Average Co-Inventor Count = 5.3

ph-index = 1


Company Filing History:

goldMedal6 out of 1,233 
 
Takeda Pharmaceutical Company Limited
 patents
where one patent can have more than one assignee

Years Active: 2025-2026

Loading Chart...
7 patents (USPTO):Explore Patents
1. 12778932 - Viral inhibitors, the synthesis thereof, and intermediates thereto (2026-11-03),
2. 12778931 - Viral inhibitors, the synthesis thereof, and intermediates thereto (2026-11-03),
3. 12527771 - Viral inhibitors, the synthesis thereof, and intermediates thereto (2026-01-20),
4. 12377078 - Viral inhibitors, the synthesis thereof, and intermediates thereto (2025-08-05),
5. 12295941 - Viral inhibitors, the synthesis thereof, and intermediates thereto (2025-05-13),
6. 12295940 - Viral inhibitors, the synthesis thereof, and intermediates thereto (2025-05-13),
7. 12286400 - Isofagomine salts, methods of use and formulations (2025-04-29),

Title: The Innovative Contributions of Jeffrey Scott DePue

Introduction

Jeffrey Scott DePue is a notable inventor based in Windham, NH (US). He has made significant contributions to the field of antiviral medications, particularly through his work on viral inhibitors. With a total of 7 patents to his name, DePue continues to push the boundaries of medical innovation.

Latest Patents

One of DePue's latest patents focuses on viral inhibitors, specifically the synthesis of maribavir and its intermediates. Maribavir is a benzimidazole riboside that serves as an orally available antiviral medication against cytomegalovirus (CMV). The patent discloses compositions comprising maribavir and methods for providing these compositions, highlighting the importance of his work in combating viral infections.

Career Highlights

DePue is currently associated with Takeda Pharmaceutical Company Limited, where he applies his expertise in pharmaceutical research and development. His work has been instrumental in advancing antiviral therapies, showcasing his commitment to improving public health through innovative solutions.

Collaborations

Throughout his career, DePue has collaborated with esteemed colleagues such as Helge Alfred Reisch and Suresh Kumar Tipparaju. These partnerships have further enriched his research and contributed to the success of his inventions.

Conclusion

Jeffrey Scott DePue's contributions to the field of antiviral medications exemplify the impact of innovation in healthcare. His work continues to pave the way for new treatments that can significantly improve patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…